DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-10.55%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$353M
AUM Growth
+$353M
(-10%)
Cap. Flow
+$9.89M
Cap. Flow
% of AUM
2.8%
Top 10 Holdings %
Top 10 Hldgs %
52.84%
Holding
90
New
8
Increased
24
Reduced
15
Closed
7
Top Buys
| 1 |
Arcus Biosciences
RCUS
|
$2.91M |
| 2 |
Mineralys Therapeutics
MLYS
|
$2.58M |
| 3 |
Stoke Therapeutics
STOK
|
$1.81M |
| 4 |
Inogen
INGN
|
$1.78M |
| 5 |
Denali Therapeutics
DNLI
|
$1.74M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$3.58M |
| 2 |
Axogen
AXGN
|
$3.07M |
| 3 |
AtriCure
ATRC
|
$1.59M |
| 4 |
Alkermes
ALKS
|
$875K |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
$816K |
Sector Composition
| 1 | Healthcare | 85.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Inogen
INGN
$213M
| $3.27M | 0.93% |
458,065
+249,275
| +119% | +$1.78M |
|
27
Insulet
PODD
$24.2B
| $3.13M | 0.89% |
11,900
-500
| -4% | -$131K |
|
|
28
Alkermes
ALKS
$4.95B
| $3.11M | 0.88% |
94,200
-26,500
| -22% | -$875K |
|
29
Kura Oncology
KURA
$732M
| $3.06M | 0.87% |
463,368
+15,000
| +3% | +$99K |
|
|
30
Stoke Therapeutics
STOK
$1.08B
| $2.95M | 0.84% |
443,998
+272,901
| +160% | +$1.81M |
|
31
Immunovant
IMVT
$2.91B
| $2.91M | 0.82% |
169,996
+62,000
| +57% | +$1.06M |
|
|
BCAX
32
Bicara Therapeutics Inc. Common Stock
BCAX
$655M
| $2.76M | 0.78% |
212,001
+106,501
| +101% | +$1.39M |
|
33
Accuray
ARAY
$165M
| $2.19M | 0.62% |
1,222,358
| – | – |
|
|
TSVT
34
DELISTED
2seventy bio
TSVT
| $2.12M | 0.6% |
429,252
| – | – |
|
35
ProQR Therapeutics
PRQR
$256M
| $2.08M | 0.59% |
1,567,561
| – | – |
|
|
CMPS
36
Compass Pathways
CMPS
$452M
| $2.03M | 0.58% |
711,046
+467,836
| +192% | +$1.34M |
|
37
Allogene Therapeutics
ALLO
$249M
| $2.01M | 0.57% |
1,380,118
+140,000
| +11% | +$204K |
|
38
TELA Bio
TELA
$65.4M
| $1.76M | 0.5% |
1,441,029
| – | – |
|
39
Align Technology
ALGN
$9.59B
| $1.75M | 0.5% |
11,000
+5,500
| +100% | +$874K |
|
|
40
Denali Therapeutics
DNLI
$2.24B
| $1.74M | 0.49% |
+127,900
| New | +$1.74M |
|
41
Astria Therapeutics
ATXS
$394M
| $1.68M | 0.48% |
314,775
+15,000
| +5% | +$80.1K |
|
42
Viking Therapeutics
VKTX
$3.02B
| $1.56M | 0.44% |
64,516
| – | – |
|
|
RGLS
43
DELISTED
Regulus Therapeutics
RGLS
| $1.48M | 0.42% |
847,176
-28,024
| -3% | -$49K |
|
|
BWAY
44
Brainsway
BWAY
$296M
| $1.48M | 0.42% |
156,533
-36,675
| -19% | -$347K |
|
45
Oric Pharmaceuticals
ORIC
$1.03B
| $1.35M | 0.38% |
+242,000
| New | +$1.35M |
|
46
Keros Therapeutics
KROS
$640M
| $1.33M | 0.38% |
130,316
| – | – |
|
47
Lexeo Therapeutics
LXEO
$266M
| $1.31M | 0.37% |
378,083
-15,000
| -4% | -$52.1K |
|
|
ITOS
48
DELISTED
iTeos Therapeutics
ITOS
| $1.27M | 0.36% |
213,347
+25,000
| +13% | +$149K |
|
|
PVLA
49
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $1.21M | 0.34% |
43,348
-28,104
| -39% | -$787K |
|
50
ARS Pharmaceuticals
SPRY
$1.08B
| $1.2M | 0.34% |
95,290
+6,500
| +7% | +$81.8K |
|